Overview

M6620 (VX-970) in Selected Solid Tumors

Status:
Active, not recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This research study is studying a drug called M6620 as a possible treatment for advanced solid tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
EMD Serono